Dickon Hayne, MD, FRCS, MBBS

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.